Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Device Tax Repeal Effort May Raise Profile Of Issue In Election Season

This article was originally published in The Gray Sheet

Executive Summary

Legislation to repeal the impending medical device excise tax will be sent to a vote on the House floor, raising the profile of the tax as a congressional election issue even as major impediments to repeal remain in the Senate. Meanwhile, the Supreme Court health care reform ruling looms.

You may also be interested in...



In Kerry’s Departure From Senate, Device Industry Will Lose A Well-Positioned Friend

Sen. John Kerry, D-Mass., has been a strong advocate for the medical imaging and device industries. His expected departure to become secretary of state could leave a hole on the critical Senate Finance Committee.

Device Industry Campaign Contributions Favor Republicans This Election

Direct contributions from individuals or company political action committees to candidates from the pure-play device industry totaled $4.7 million to Republicans and $2.9 million to Democrats, as of Oct. 31. This clear edge toward Republicans is a shift from prior election cycles.

Device Tax Repeal Tops AdvaMed Priority List For Fiscal-Cliff Bill

The post-election, “lame-duck” Congress will face the prospect of letting massive federal spending cuts take effect and multiple tax increases kick in if it does not take action. Device firms hope to leverage the situation to repeal the looming medical device excise tax and make FDA user-fee fixes while avoiding more Medicare provider cuts.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel